Kurv Tesla(TSLA)收益溢價策略主動型ETF TSLP 深 滬
等待開盤 03-26 09:30:00 美东时间
18.8973
+0.117
+0.62%
華盛通- 最 高19.38
- 今 開19.115
- 成交量 1.70万股
- 最 低 18.865
- 昨 收 18.78
- 總市值 1965.32万
- 52周最高 24.919
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 10.06
- 委 比 2.91%
- 總股本 104.00万
- 歷史最高 24.1395
- 量 比 1.04
- 振 幅 2.74%
- 歷史最低 2.1023
- 每 手 1
- 風險率 3.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults
Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal
03-23 11:15
Pfizer's Phase 2 Study Investigating Tilrekimig In Adults With Moderate To Severe Atopic Dermatitis Met Its Primary Efficacy Endpoint
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placeboTilrekimig (PF-07275315) was
03-09 18:47
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%)
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%) Aclaris reported a net loss of USD 19.8 million in Q4 2025 and USD 64.9 million for FY 2025. Total revenue was USD 1.3 million in Q4 2025 and USD 7.8 million in FY 2025. R&D expenses rose to USD 16.6 million in Q4 2025 and USD 52.6 million in FY
02-26 19:58
Aclaris Initiates Phase 1b Asthma Trial of Bispecific Antibody ATI-052
Aclaris Initiates Phase 1b Asthma Trial of Bispecific Antibody ATI-052 Aclaris Therapeutics Inc. has initiated a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept trial evaluating ATI-052, an investigational bispecific anti-TSLP/IL-4Rα antibody, in approximately 16 asthma patien
02-24 20:01
Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma
Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma Upstream Bio Inc. announced that it will report top-line results from the Phase 2 VALIANT trial of verekitug, a thymic stromal lymphopoietin (TSLP) receptor antagonist in development for severe asthma, o
02-11 07:00
Apogee Therapeutics Reports Positive Phase 1 Results for APG333 in Respiratory Disease Study
Apogee Therapeutics Inc. has announced positive interim results from a Phase 1 clinical trial of APG333, a novel half-life extended TSLP antibody. The study was a double-blind, placebo-controlled, fir...
2025-11-10 20:01
华盛早报 | 深夜大涨！谷歌市值突破3万亿美元大关；特朗普欲废除美股季报制度，改为仅披露半年报
深夜大涨！谷歌市值突破3万亿美元大关；特朗普欲废除美股季报制度，改为仅披露半年报；大摩料本周降息后美股涨势或“熄火”，但回调仍是买入机会>>
2025-09-16 08:13
Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps
Upstream Bio Inc., a clinical-stage company focused on developing treatments for inflammatory diseases, has announced that it will soon present top-line data from its Phase 2 VIBRANT trial of the drug...
2025-09-02 05:00
BRIEF-Harbour BioMed's Monoclonal Antibody, Enters Global Phase 2 Trial For Asthma
July 23 (Reuters) - Hbm Holdings Ltd 2142.HK: HBM9378/WIN378, A LONG-ACTING, FULLY HUMAN ANTI-TSLP ANTIBODY, ENTERS GLOBAL PHASE 2 POLARIS TRIAL FOR ASTHMA HBM HOLDINGS LTD - PHASE 2 TRIAL DATA FOR HB...
2025-07-23 20:40
